论文部分内容阅读
目的观察视网膜中央静脉堵塞及视网膜分支静脉堵塞继发黄斑水肿后玻璃体腔内注射雷珠单抗(Ranibizumab)的疗效。方法选取于2015年5月~2016年6月确诊的视网膜静脉堵塞(RVO)患者共90例(90眼),分为视网膜分支静脉阻塞(BRVO)组共58例(58眼),视网膜中央静脉阻塞(CRVO)组共32例(32眼),所有患者采用1+PRN的方案进行玻璃体内注射雷珠单抗,比较两组患者治疗前后患眼最佳矫正视力(BCVA)、黄斑中心凹厚度(CMT)、眼压(IOP)等指标。结果所有患者随访3个月,BRVO组与CRVO组患者治疗前性别、年龄、IOP比较,差异无统计学意义(P>0.05)。BRVO组与CRVO组BCVA比较,术前BCVA差异有统计学意义(P<0.05);两组治疗后1d分别与治疗前相比,差异均无统计学意义(P>0.05);两组治疗后1周、1个月、3个月分别与治疗前比较,差异均有统计学意义(P<0.05);BRVO组与CRVO组CMT比较,两者术前CMT差异有统计学意义(P<0.05);两组治疗后1周、1个月、3个月与治疗前比较,差异有统计学意义(P<0.05);BRVO组与CRVO组IOP比较,两者治疗后1d、1周、1个月、3个月与治疗前比较,差异均无统计学意义(P>0.05)。结论玻璃体腔内注射雷珠单抗对于治疗BRVO及CRVO均有效,都能促进RVO患者BCVA的提高,改善黄斑水肿。
Objective To observe the efficacy of intravitreal Ranibizumab after central retinal vein occlusion and retinal vein occlusion secondary to macular edema. Methods A total of 90 patients (90 eyes) with retinal vein occlusion (RVO) diagnosed from May 2015 to June 2016 were divided into 58 cases (58 eyes) in the branch of retinal vein branch occlusion (BRVO) group, the central retinal vein Intravenous injection of ranibizumab (1 PRN) was used in 32 patients (32 eyes) in CRVO group. The best corrected visual acuity (BCVA), macular foveal thickness (CMT), intraocular pressure (IOP) and other indicators. Results All patients were followed up for 3 months. There was no significant difference in gender, age and IOP between BRVO group and CRVO group before treatment (P> 0.05). The difference of BCVA between the BRVO group and the CRVO group was statistically significant (P <0.05). There was no significant difference in the preoperative BCVA between the two groups after treatment (P> 0.05) The difference was statistically significant (P <0.05) between the BRVO group and the CRVO group at 1 week, 1 month and 3 months, respectively, compared with those before treatment ). The difference between the two groups was statistically significant (P <0.05) at 1 week, 1 month and 3 months after treatment. Compared with IOP in CRVO group, Months, 3 months and before treatment, the difference was not statistically significant (P> 0.05). Conclusion Intravitreal injection of ranibizumab is effective in treating both BRVO and CRVO, which can promote the increase of BCVA and improve the macular edema in RVO patients.